nach oben

Clinical Rheumatology

Erschienen in:

01.03.2009 | Original Article

Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus

verfasst von: Márcio Veronesi Fukuda, Simone Chinwa Lo, Cláudia Salvini de Almeida, Samuel Katsuyuki Shinjo

Erschienen in: Clinical Rheumatology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with various clinical and serological manifestations. Previous studies have shown the association of SLE and anti-Ro antibody with a series of clinical manifestations. We investigated this association in Brazilian patients with SLE. Five hundred and nine consecutive patients who fulfilled the revised American College of Rheumatology criteria for the SLE were enrolled in the study from June to December 2007. All patients were from our Service of Rheumatology, School of Medicine, University of São Paulo, Brazil. Frequencies of a series of laboratorial and clinical manifestations were calculated. Anti-Ro antibody was associated to anti-La antibody, female, and cutaneous vasculitis. In multivariate analysis, patients with anti-Ro antibody has 1.63 (95% CI 1.07–2.50) more risk to develop cutaneous vasculitis than patients without this antibody. Our data have demonstrated that anti-Ro antibody is an independent useful serologic marker for cutaneous vasculitis.

Sibilia J (1998) Ro (SS-A) and anti-Ro (SS-A): an update. Rev Rhum Engl Ed 65:45–57PubMed

Harley JB, Scofield RH, Reichlin M (1992) Anti-Ro in Sjögren’s syndrome and systemic lupus erythematosus. Rheum Dis Clin North Am 18:337–358PubMed

Penner E, Reichlin M (1982) Primary biliary cirrhosis associated with Sjögren’s syndrome: evidence for circulating and tissue-deposited Ro/anti-Ro immune complexes. Arthritis Rheum 25:1250–1253PubMedCrossRef

Cavazzana I, Franceschini F, Quinzanini M, Manera C, Del Papa N, Maglione W, Comina D, Radice A, Sinico RA, Cattaneo R (2006) Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin Exp Rheumatol 24:59–64PubMed

Wolin SL, Reinisch KM (2006) The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments or structure. Autoimmun Rev 5:367–372PubMedCrossRef

Provost TT, Levin LS, Watson RM, Mayo M, Ratrie H 3rd (1991) Detection of anti Ro(SSA) antibodies by gel double diffusion and a sandwich ELISA in systemic and subacute cutaneous lupus erythematosus and Sjogren’s syndrome. J Autoimmun 4:87–96PubMedCrossRef

Clark G, Reichlin M, Tomasi TB (1969) Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J Immunol 102:117–122PubMed

Maddison PJ, Mogavero M, Provost TT, Reichlin M (1976) The clinical significance of autoantibodies to a soluble cytoplasmic antigen in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 6:189–195

Synkowski DR, Reichlin M, Provost TT (1982) Serum autoantibodies in systemic lupus erythematosus and correlation with cutaneous features. J Rheumatol 9:380–385PubMed

10.

Hochberg MC, Boyd RE, Aheran JM, Arnett FC, Bias WB, Provost TT, Stevens MB (1985) Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markerjs in 150 patients with emphasis on demographic subsets. Medicine 64:285–295PubMedCrossRef

11.

Mond CB, Peterson MG, Rothfield NF (1989) Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum 32:202–204PubMedCrossRef

12.

Sutej PG, Gear AJ, Morrison RC, Tikly M, de Beer M, Dos Santos L, Sher R (1989) Photosensitivity and anti-Ro (SS-A) antibodies in black patients with systemic lupus erythematosus (SLE). Br J Rheumatol 28:321–324PubMedCrossRef

13.

Kurien BT, Newland J, Paczkowski C, Moore KL, Scofield RH (2000) Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen. Clin Exp Immunol 120:209–217PubMedCrossRef

14.

Vilá LM, Molina MJ, Mayor AM, Peredo RA, Santaella ML, Vilá S (2006) Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus. Lupus 15:892–898PubMedCrossRef

15.

Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, Piette JC (2005) Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus 14:660–664PubMedCrossRef

16.

Clancy RM, Neufing PJ, Zheng P, O’Mahony M, Nimmerjahn F, Gordon TP, Buyon JP (2006) Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and –SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 116:2413–2422PubMed

17.

La zzerini PE, Capecchi PL, Guideri F, Acampa M, Galeazzi M, Laghi-Pasini F (2006) Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev 5:306–313PubMedCrossRef

18.

Shahin AA, Shahin HA, Hamid MA, Amin MA (2004) Cardiac involvement in patients with systemic lupus erythematosus and correlation of valvular lesions with anti-Ro/SS-A and anti-La/SS-B antibody levels. Mod Rheumatol 14:117–122PubMedCrossRef

19.

Oshiro AC, Derbes SJ, Stopa AR, Gedalia A (1997) Anti-Ro/SS-A and anti-La/SS-B antibodies associated with cardiac involvement in childhood systemic lupus erythematosus. Ann Rheum Dis 56:i272–i274CrossRef

20.

Alexander EL, Arnett FC, Provost TT, Stevens MB (1983) Sjögren’s syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 98:155–159PubMed

21.

Moutsopoulos HM, Zerva LV (1990) Anti-Ro (SSA)/La (SSB) antibodies and Sjögren’s syndrome. Clin Rheumatol 9(1 Suppl 1):123–130PubMedCrossRef

22.

Alexander EL, Provost TT (1983) Cutaneous manifestations of primary Sjögren’s syndrome: a refletion of vasculitis and association with anti-Ro (SSA) antibodies. J Invest Dermatol 80:386–391PubMedCrossRef

23.

Alexander EL, Provost TT (1987) Sjögren’s syndrome. Association of cutaneous vasculitis with central nervous system disease. Arch Dermatol 123:801–810PubMedCrossRef

24.

Alexander EL, Hirsch TJ, Arnett FC, Provost TT, Stevens MB (1982) Ro (SSA) and La (SSB) antibodies in the clinical spectrum of Sjögren’s syndrome. J Rheumatol 9:239–246PubMed

25.

Cho CS, Park SH, Min JK, Lee SH, Kim HY (1997) Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren’s syndrome. Korean J Intern Med 12:176–181PubMed

26.

Boire G, Ménard HA (1988) Clinical significance of anti-Ro (SSA) antibody in rheumatoid arthritis. J Rheumatol 15:391–394PubMed

27.

Magro CM, Crowson AN (2003) The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients. J Cutan Pathol 30:1–10PubMedCrossRef

28.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725PubMedCrossRef

29.

McCauliffe DP (1997) Cutaneous diseases in adults associated with Anti-Ro/SS-A autoantibody production. Lupus 6:158–166PubMedCrossRef

30.

Dubois EL, Tuffanelli DL (1964) Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA 190:104–111PubMed

31.

Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH (1954) Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 33:291–437CrossRef

32.

Yell JA, Mbuagbaw J, Burge SM (1996) Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 135:355–362PubMedCrossRef

33.

Grigor R, Edmonds J, Lewkonia R, Bresnihan B, Hughes GR (1978) Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis 37:121–128PubMedCrossRef

34.

Bouaziz JD, Barete S, Le Pelletier F, Amoura Z, Piette JC, Francès C (2007) Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases. Lupus 16:163–167PubMed

35.

Watson R (1989) Cutaneous lesions in systemic lupus erythematosus. Med Clin North Am 73:1091–1111PubMed

36.

Drenkard C, Villa AR, Reyes E, Abello M, Alarcón-Segovia D (1997) Vasculitis in systemic lupus erythematosus. Lupus 6:235–242PubMedCrossRef

37.

Provost TT, Watson R, Simmons-O’Brien E (1996) Anti-Ro (SS-A) antibody positive Sjögren’s/lupus erythematosus overlap syndrome. Lupus 6:105–111CrossRef

Titel: Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus
verfasst von: Márcio Veronesi Fukuda
Simone Chinwa Lo
Cláudia Salvini de Almeida
Samuel Katsuyuki Shinjo
Publikationsdatum: 01.03.2009
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 3/2009
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-008-1043-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

CT-guided fine-needle aspiration in vertebral osteomyelitis: true usefulness of a common practice

Influence of social support on health-related quality of life in patients with systemic lupus erythematosus

Preeclampsia, dilated cardiomyopathy and renal failure as the first manifestation of systemic lupus erythematosus: a case report

Overall reduction in antibody production could contribute to generate pathogenic autoantibodies and autoimmune manifestations

Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study